sphingosine-1-phosphate and Uremia

sphingosine-1-phosphate has been researched along with Uremia* in 1 studies

Other Studies

1 other study(ies) available for sphingosine-1-phosphate and Uremia

ArticleYear
Effects of apolipoprotein M in uremic atherosclerosis.
    Atherosclerosis, 2017, Volume: 265

    Chronic kidney disease is characterized by uremia and causes premature death, partly due to accelerated atherosclerosis. Apolipoprotein (apo) M is a plasma carrier protein for the lipid sphingosine-1-phosphate (S1P). The Apom-S1P complex associates with HDL, and may contribute to its anti-atherosclerotic effects. The role of Apom/S1P in atherosclerosis is presently controversial and has not been explored in a uremic setting. We aimed to explore whether plasma concentrations of Apom/S1P are altered by uremia and whether Apom overexpression or deficiency affects classical and uremic atherosclerosis.. Mild to moderate uremia was induced by subtotal nephrectomy (NX) in 86-92 Apoe-deficient mice that were either Apom-wild type, Apom-deficient, or overexpressed Apom (∼10 fold). The effects of uremia on plasma Apom/S1P and atherosclerosis were evaluated and compared to non-nephrectomized controls.. Uremia increased plasma Apom by ∼25%, but not S1P. Plasma S1P was elevated by ∼300% in mice overexpressing Apom, and decreased by ∼25% in Apom-deficient mice. Apom overexpression augmented aortic root atherosclerosis and plasma cholesterol. In contrast, aortic arch atherosclerosis was unaffected by the Apom genotype. There was no effect of Apom-deficiency or Apom overexpression on uremic atherosclerosis.. This study highlights the complexity of Apom/S1P in atherosclerosis and challenges the notion that the Apom/S1P complex is anti-atherogenic, at least in Apoe-deficient mice.

    Topics: Animals; Aortic Diseases; Apolipoproteins M; Atherosclerosis; Cholesterol; Disease Models, Animal; Female; Genetic Predisposition to Disease; Humans; Lysophospholipids; Mice, Inbred C57BL; Mice, Knockout, ApoE; Nephrectomy; Phenotype; Plaque, Atherosclerotic; Sphingosine; Uremia

2017